RoyGulickMD

Professor, Medicine, Weill Cornell Medical College

Overview of Dr. Gulick

Dr. Roy Gulick is an infectious disease specialist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 31 years. Dr. Gulick accepts several types of health insurance, listed below. He is one of 142 doctors at New York-Presbyterian Hospital and one of 45 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Infectious Disease. He has more than 100 publications and over 500 citings.

Office
Division of Infectious Diseases Weill Cornell Medicine
1300 York Ave
New York, NY 10065
Book by Phone+1(928) 325-1630

Fax+1 212-746-8852

Education & Training

School of Public Health, Harvard UniversityM.P.H., 1991 - 1993
Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 1990 - 1991
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1986 - 1989
Columbia University Vagelos College of Physicians and SurgeonsClass of 1986
Johns Hopkins UniversityB.A., 1978 - 1982

Certifications & Licensure

NY State Medical License 1988 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

Lifetime Achievement Award “for his invaluable contributions in the field of HIV medicine, medical education, and research” HIV Congress, 2012
Clinical Educator Award HIV Medical Association, 2012
Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2012-2015
Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2012-2015
Research in Action Award Treatment Action Group, 2009
Fellow Infectious Diseases Society of America, 2009
Clinical Infectious Diseases Award for Outstanding Review 2006
Elected Member The American Society for Clinical Investigation, 2006
Excellence in Teaching Award (Advanced Basic Science Course) Weill Cornell Medical College, 2005
Advisory Committee Service Award in Recognition of Distinguished Service U.S. Food and Drug Administration, 2005
Mid-Career Investigator Award in Patient-Oriented Research (K24) National Institute of Allergy and Infectious Disease, National Institutes of Health, 2003
Companero (Friend) Award, for commitment to HIV/AIDS research Latino Commission on AIDS, New York, NY, 2002
Most Scientifically Innovative Presentation Second International Workshop on Salvage Therapy for HIV Infection; Toronto, Canada, 1999
Alpha Omega Alpha National Medical Honor Society, Columbia College of Physicians and Surgeons, 1986
Omicron Delta Kappa National Leadership Fraternity, Johns Hopkins University, 1981
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir
Completed
Not Applicable
A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible
Completed
Phase 2
A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients
Completed
Phase 2
A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir
Completed
Phase 2
Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection
Completed
Phase 3
Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients Start of enrollment: 2004 May 01
Completed
Phase 2
Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection Start of enrollment: 2005 Mar 01
Terminated
Phase 4
Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression Start of enrollment: 2009 Jan 01
Completed
Not Applicable
Respiratory Virus Hospitalization Study (FLU 003 Plus) Start of enrollment: 2009 Aug 01
Recruiting
Roles: Contact, Principal Investigator
HIV Adherence Bottle Intervention Trial Start of enrollment: 2015 May 01
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

938 citations
Severe Covid-19
Roy M. Gulick, Fernando J. Martinez
The New England Journal of Medicine. 2020-05-15
21 citations
Case-control study of diabetes mellitus in HIV-infected patients.
Cecilia Yoon, Roy M. Gulick, Donald R. Hoover, Carlos M. Vaamonde, Marshall J. Glesby
Journal of Acquired Immune Deficiency Syndromes. 2004-12-01
583 citations
Maraviroc for Previously Treated Patients with R5 HIV-1 Infection
Roy M. Gulick, Jacob Lalezari, James Goodrich, Nathan Clumeck, Edwin DeJesus
The New England Journal of Medicine. 2008-10-02

Journal Articles

Combination Therapy with Anti-HIV-1 Antibodies Maintains Viral Suppression
Michael S Seaman, Katrina Millard, Marina Caskey, Michel C Nussenzweig, Roy M Gulick, Thiago Y Oliveira, Nature
Safety and Antiviral Activity of Combination HIV-1 Broadly Neutralizing Antibodies in Viremic Individuals
Roy M Gulick, Thiago Y Oliveira, Marina Caskey, Michel C Nussenzweig, Michael S Seaman, Katrina Millard, Nature
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Post-Treatment Controllers Identified from 14 Clinical Studies
Elizabeth Connick, Michael C Sneller, Jonathan Z Li, Paul Volberding, Daniel R Kuritzkes, Robert T Schooley, David Margolis, Daniel Skiest, John W Mellors, Ronald Mits..., The Journal of Infectious Diseases
5-year safety evaluation of maraviroc in HIV-1-infected, treatment-experienced patients
Gulick RM, Fatkenheuer G, Burnside R, Hardy WD, Nelson MR, Goodrich J, Mukwaya G, Portsmouth S, Heera JR, JAIDS, 1/1/2014
Modeling immunologic endpoints as a function of time of switch to second-line ART with incomplete data on switching times
Johnson BA, Ribaudo H, Gulick RM, Eron JJ, Biometrics, 1/1/2013
Invasive meningococcal disease in men who have sex with men
Simon MS, Weiss D, Gulick RM, Ann Intern Med, 1/1/2013
Racial differences in response to antiretroviral therapy for HIV infection: an AIDS Clinical Trials Group (ACTG) study analysis
Ribaudo HJ, Smith KY, Robbins GK, Flexner C, Haubrich R, Chen Y, Fischl MA, Schackman BR, Riddler SA, Gulick RM, Clin Infect Dis, 1/1/2013
Regulatory T cells and the risk of CMV end-organ disease in AIDS patients
Weinberg A, Bosch R, Bennett K, Tovar-Salazar A, Benson C, Collier AC, Behm T, Zolopa A, Gulick RM, Wohl D, Polsky B, Erice A, Jacobson M, JAIDS, 1/1/2013
HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that correct in the presence of drug
Putcharoen O, Lee SH, Henrich T, Hu Z, Vanichanan J, Coakley E, Greaves W, Gulick R, Kuritzkes D, Tsibris A, J Virol, 1/1/2012
Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development
Morris BL, Scott CA, Wilkin TJ, Sax PE, Gulick RM, Freedberg KA, Schackman BR, HIV Clin Trials, 1/1/2012
Differential use of CCR5 by HIV-1 clinical isolates resistant to small molecule CCR5 antagonists
Henrich TJ, Lewine NRP, Lee S-H, Rao SSP, Berro R, Gulick RM, Moore JP, Tsibris AMN, Kuritzkes DR, Antimicrob Agents Chemother, 1/1/2012
Novel clinical trials designs for the development of new antiretroviral agents
Mani N, Murray J, Gulick RM, Josephson F, Miller V, Miele P, Strobos J, Struble K, AIDS, 1/1/2012
Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures
Tsibris AM, Hu Z, Paredes R, Leopold KE, Putcharoen O, Schure A, Mazur N, Coakley E, Su Z, Gulick RM, Kuritzkes DR, J Virol, 1/1/2012
Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti
Charles M, Leger PD, Severe P, Guiteau C, Apollon A, Gulick RM, Johnson WD, Pape JW, Fitzgerald DW, J Intern AIDS Soc, 1/1/2012
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4+ T-cell recovery despite sustained virologic suppression: ACTG A5256
Wilkin TJ, Lalama CM, McKinnon J, Gandhi RT, Lin N, Landay A, Ribaudo H, Fox L, Currier JS, Mellors JW, Gulick R, Tenorio AR, J Infect Dis, 1/1/2012
Evaluating the effect of early versus late ARV regimen change if failure on an initial regimen: Results from the AIDS Clinical Trials Group Study A5095
Li L, Eron JJ, Ribaudo H, Gulick RM, Johnson BA, J Am Stat Assoc, 1/1/2012
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants
Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW, Pharmacogenet Genomics, 1/1/2012
CCR5 antagonism in HIV infection: Current concepts and future opportunities
Wilkin TJ, Gulick RM, Ann Rev Med, 1/1/2012
Next-generation oral preexposure prophlaxis: beyond tenofovir
Abraham BK, Gulick R, Curr Opin HIV AIDS, 1/1/2012
Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in A...
Grady BJ, Torstenson ES, McLaren PJ, DE Bakker PI, Haas DW, Robbins GK, Gulick RM, Haubrich R, Ribaudo H, Ritchie MD, Pac Symp Biocomput, 1/1/2011
Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure
Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes D, Stevenson M, PLoS Pathogens, 1/1/2011
Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity
Wilkin TJ, Goetz MB, Leduc R, Skowron G, Su Z, Chan ES, Heera J, Chapman D, Spritzler J, Reeves JD, Gulick RM, Coakley E, Clin Infect Dis, 1/1/2011
Change in high-sensitivity C-reactive protein (hsCRP) levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals
Shikuma CM, Ribaudo HJ, Zheng Y, Gulick RM, Meyer WA, Tashima KT, Bastow B, Kuritzkes DR, Glesby MJ, AIDS Res Hum Retroviruses, 1/1/2011
Comparative Effectiveness of Initial Antiretroviral Therapy Regimens: ACTG 5095 and 5142 Clinical Trials Relative to ART-CC Cohort Study
Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R, Napravnik S, Abgrall S, Phillips A, Harris R, Gill MJ, de Wolf F, Hogg R, Günthard HF, Chene G, D'Ar..., J Acquir Immune Defic Syndr, 1/1/2011
Pharmacogenomics of HIV Therapy: Summary of a Workshop Sponsored by the National Institute of Allergy and Infectious Diseases
Haas DW, Kuritzkes D, Ritchie MD, Amur S, Gage BF, Maartens G, Masys D, Fellay J, Phillips E, Ribaudo HJ, Freedberg KA, Petropoulos C, Manolio TA, Gulick RM, Haubrich ..., HIV Clin Trials, 1/1/2011
Join now to see all

Press Mentions

CDC Warns of Rise in Drug-Resistant Stomach Bug – NBC ChicagoFebruary 28th, 2023
The CDC Warns of a Rise in Drug-Resistant Shigella BacteriaFebruary 27th, 2023
A Public Health Success Story: How the Mpox Crisis Was Controlled Within 6 MonthsFebruary 2nd, 2023
Join now to see all

Insurance Accepted

Aetna Choice POS II
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida BlueSelect
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
Great West PPO
Healthfirst New York
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment